This month’s portfolio company spotlight features stories from Abound Bio and BlueSphere Bio.
Yufan Biotechnologies has now partnered with Abound Bio, Inc, a life sciences company with world-renowned expertise in finding antibodies to direct CAR T-cells against cancer targets. The three-year partnership covers the incorporation of antibodies to novel cancer targets into the enhanced, HPK1-inhibited CAR T-cell platform.
Researchers have created a drug called “Ab8” that holds the potential to treat COVID-19 and prevent infection in susceptible populations. Ab8 has been licensed for worldwide development by Abound Bio, a newly formed UPMC-backed company. Clinical trials, which require FDA approval, will start in the beginning of 2021.
BlueSphere Bio Names Dr. James Onuffer VP of Product Development in Preparation for Clinical Program
Immuno-oncology startup BlueSphere Bio has appointed James Onuffer, Ph.D., as its vice president of product development. In this newly established role, Onuffer will build and manage the product development infrastructure, lead efforts in cellular engineering, and oversee preclinical studies, process development and manufacturing to meet regulatory guidelines and business goals.
